Phagelux to Present at Biotech Showcase 2020 in San Francisco

Thursday, January 9, 2020 Press Release
Email Print This Page Comment bookmark
Font : A-A+

Phagelux Will Update the Status of Its Product Pipeline

MONTREAL and WUHAN, China, Jan. 9, 2020 /PRNewswire/ - Phagelux, Inc., a clinical-stage ready biotechnology company focused on the discovery and development of bacteriophages and lysins to treat and prevent antibiotic resistant infections, today announced that it has scheduled a company presentation at Biotech Showcase 2020. The presentation will be given by Mark Engel, CEO, on Tuesday, January 14, 2020 at 3:45pm PST in the Franciscan B Room of the Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA.  The presentation will update the corporate and pipeline status of the company.

According to Mr. Engel, "Developing and launching new antibacterials is a highly risky undertaking. Not only does one need to get the science correct.  But, for the product to be financially successful, one also needs to develop novel business approaches.  We believe our products will not only significantly reduce topical infection rates but also reduce overall healthcare costs associated with infections.  In other words, the standard of care will change since healthcare providers and insurance companies will achieve both better patient outcomes and cost savings by using our products."

About Phagelux, Inc.

Phagelux utilizes phages, lysins and other biologics and related delivery technologies to create antibacterial products and solutions. Phagelux is headquartered in Shanghai with a bacteriophage and bio-engineering laboratory and manufacturing facility in Montreal and a lysin and related technologies lab in Wuhan, China. Phagelux is primarily developing topical products focusing on the prevention of antibiotic resistant infections. 

Cision View original content:http://www.prnewswire.com/news-releases/phagelux-to-present-at-biotech-showcase-2020-in-san-francisco-300984289.html

SOURCE Phagelux, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store